Skip to Main Content

Author Details

Junia V Melo
University of Adelaide
1984
198
63
PMIDPaper TitleJournal TitlePublished Year
36940020Another Year to Celebrate Advances in Clinical Hematology.Clin Hematol Int2023
34595460One Year into the COVID-19 Pandemic.Clin Hematol Int2021
31628323A kinase-independent role for CDK8 in BCR-ABL1<sup>+</sup> leukemia.Nat Commun2019
29165716Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition.J Natl Cancer Inst2018
29772458Phenotyping and Target Expression Profiling of CD34<sup>+</sup>/CD38<sup>-</sup> and CD34<sup>+</sup>/CD38<sup>+</sup> Stem- and Progenitor cells in Acute Lymphoblastic Leukemia.Neoplasia2018
28978065The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells.Oncotarget2017
25904380Pro-survival role of protein kinase C epsilon in Philadelphia chromosome positive acute leukemia.Leuk Lymphoma2016
25814077Natural course and biology of CML.Ann Hematol2015
26413753Identification of ILK as a novel therapeutic target for acute and chronic myeloid leukemia.Leuk Res2015
24681707Identification of heat shock protein 32 (Hsp32) as a novel target in acute lymphoblastic leukemia.Oncotarget2014
24590311Synergistic effects of proteasome inhibitor carfilzomib in combination with tyrosine kinase inhibitors in imatinib-sensitive and -resistant chronic myeloid leukemia models.Oncogenesis2014
22824785SOCS2 is dispensable for BCR/ABL1-induced chronic myeloid leukemia-like disease and for normal hematopoietic stem cell function.Leukemia2013
24130846A target-disease network model of second-generation BCR-ABL inhibitor action in Ph+ ALL.PLoS One2013
23704092Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.Blood2013
23588714Distribution of genomic breakpoints in chronic myeloid leukemia: analysis of 308 patients.Leukemia2013
23232286Nilotinib shows prolonged intracellular accumulation upon pulse-exposure: a novel mechanism for induction of apoptosis in CML cells.Leukemia2013
22858985Transcriptional suppression of BACH2 by the Bcr-Abl oncoprotein is mediated by PAX5.Leukemia2013
21859430Clonal and lineage analysis of somatic DNMT3A and JAK2 mutations in a chronic phase polycythemia vera patient.Br J Haematol2012
23051844Cancer stem cell definitions and terminology: the devil is in the details.Nat Rev Cancer2012
22815843Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells.PLoS One2012
22372463BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia.Br J Haematol2012
22018447Imatinib mesylate at therapeutic doses has no impact on folliculogenesis or spermatogenesis in a leukaemic mouse model.Leuk Res2012
20844563Do we have to kill the last CML cell?Leukemia2011
22160025Minimal residual disease and discontinuation of therapy in chronic myeloid leukemia: can we aim at a cure?Hematology Am Soc Hematol Educ Program2011
22147770Chronic myeloid leukemia: the basis of treatment for tomorrow.Haematologica2011
21821701SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia.Blood2011
21890264Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients.Cancer Lett2011
21299456Mechanisms of resistance to BCR-ABL kinase inhibitors.Leuk Lymphoma2011
21332713RUNX1 mutations are rare in chronic phase polycythaemia vera.Br J Haematol2011
20010623Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy.Leukemia2010
21368869Functional phosphoproteomic analysis reveals cold-shock domain protein A to be a Bcr-Abl effector-regulating proliferation and transformation in chronic myeloid leukemia.Cell Death Dis2010
21051563Wrapping BCR-ABL: it's in the bag.Blood2010
20811403Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.Leukemia2010
20703256Analysis of genomic breakpoints in p190 and p210 BCR-ABL indicate distinct mechanisms of formation.Leukemia2010
20462961In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib.Blood2010
20130598Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors.Leukemia2010
20228846Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming.Oncogene2010
20417730Gaining insights into the Bcr-Abl activity-independent mechanisms of resistance to imatinib mesylate in KCL22 cells: a comparative proteomic approach.Biochim Biophys Acta2010
20299508Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants.Blood2010
19881535Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma1-driven activation of mTOR/p70S6-kinase pathway.Oncogene2010
19837975A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib.Blood2010
18971950Imatinib sensitivity as a consequence of a CSF1R-Y571D mutation and CSF1/CSF1R signaling abnormalities in the cell line GDM1.Leukemia2009
20616897Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib.Onco Targets Ther2009
19880502Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?Blood2009
19698927The impact of gene profiling in chronic myeloid leukaemia.Best Pract Res Clin Haematol2009
19663881Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells.Br J Pharmacol2009
19377081The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinib.Haematologica2009
19401345Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells.Clin Cancer Res2009
19157685Proteasome proteolytic profile is linked to Bcr-Abl expression.Exp Hematol2009
19268365CD40 and B-cell receptor signalling induce MAPK family members that can either induce or repress Bcl-6 expression.Mol Immunol2009
  • 1 - 50 of 198

Recommended Authors

Paulo Vidal Campregher
Hospital Israelita Albert Einstein
Career Start Year 2007
Number of shared co-authors 1
Christopher A Eide
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2006
Number of shared co-authors 16
Anupriya Agarwal
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2006
Number of shared co-authors 13
Ronan Swords
Oregon Health and Science University
Career Start Year 2004
Number of shared co-authors 10
Anna M Eiring
Texas Tech University Health Sciences Center at El Paso
Career Start Year 2004
Number of shared co-authors 10
Vivian G Oehler
Fred Hutchinson Cancer Center.
Career Start Year 2003
Number of shared co-authors 11
Thomas Ernst
Universitatsklinikum Jena
Career Start Year 2002
Number of shared co-authors 5
Jeffrey W Tyner
Oregon Health & Science University School of Medicine
Career Start Year 2002
Number of shared co-authors 20
Farhad Ravandi
University of Texas M.D. Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 8
Nikolas von Bubnoff
University Hospital of Schleswig-Holstein
Career Start Year 1997
Number of shared co-authors 3
Bill H Chang
Oregon Health and Science University
Career Start Year 1993
Number of shared co-authors 8
Ravi Bhatia
University of Alabama at Birmingham
Career Start Year 1992
Number of shared co-authors 11
Derek L Stirewalt
Fred Hutchinson Cancer Center
Career Start Year 1992
Number of shared co-authors 7
Michael W Becker
James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester
Career Start Year 1992
Number of shared co-authors 1
Arndt Borkhardt
Hematology and Clinical Immunology, Heinrich Heine University Dusseldorf
Career Start Year 1992
Number of shared co-authors 2
Thomas O'Hare
Huntsman Cancer Institute, University of Utah
Career Start Year 1991
Number of shared co-authors 17
Claude Preudhomme
Lille University Hospital, INSERM UMR-S7, CNRS UMR9020, Lille University.
Career Start Year 1989
Number of shared co-authors 8
Suzanne Kamel-Reid
Toronto General Hospital, University Health Network, University of Toronto
Career Start Year 1988
Number of shared co-authors 5
Robert H Collins
University of Texas Southwestern Medical Center
Career Start Year 1987
Number of shared co-authors 9
Richard J Jones
Sidney Kimmel Cancer Center, Johns Hopkins University
Career Start Year 1986
Number of shared co-authors 2
Marcela Gronda
Princess Margaret Cancer Centre
Career Start Year 1985
Number of shared co-authors 0
Torsten Haferlach
Taussig Cancer Institute, Cleveland Clinic
Career Start Year 1983
Number of shared co-authors 11
Jami McLaughlin
University of California los angeles
Career Start Year 1983
Number of shared co-authors 2
Bertram Opalka
University Hospital Essen.
Career Start Year 1982
Number of shared co-authors 1
Steven M Kornblau
The University of Texas MD Anderson Cancer Center
Career Start Year 1980
Number of shared co-authors 9
Ulrich D??hrsen
University Hospital Essen, University of Duisburg-Essen
Career Start Year 1979
Number of shared co-authors 2
Sanford A Stass
University of Maryland School of Medicine
Career Start Year 1977
Number of shared co-authors 3
Alex Look
Dana-Farber Cancer Institute
Career Start Year 1975
Number of shared co-authors 12
Owen N Witte
University of California los angeles
Career Start Year 1972
Number of shared co-authors 3
Robin Fo??
Sapienza University.
Career Start Year 1968
Number of shared co-authors 3

Collaborators

Michael W Deininger
University of Utah Huntsman Cancer Institute
Co-authored papers 15
Brian J Druker
Oregon Health & Science University
Co-authored papers 5
Stephen G O'Brien
Newcastle University
Co-authored papers 3
Stephanie G Willis
OHSU Cancer Institute
Co-authored papers 2
Nathanael S Gray
Harvard Medical School
Co-authored papers 2
Jamshid S Khorashad
Institute of Cancer Research
Co-authored papers 2
Hagop Kantarjian
The University of Texas MD Anderson Cancer Center
Co-authored papers 2
Yaron Turpaz
Pte. Ltd.
Co-authored papers 1
Catherine J Wu
Co-authored papers 1
Charles L Sawyers
Memorial Sloan Kettering Cancer Center
Co-authored papers 1
Huib Ovaa
Leiden University Medical Center
Co-authored papers 1
Robert Brown
Ovarian Cancer Action Research Centre, Imperial College London
Co-authored papers 1
Alan Entwistle
The Ludwig Institute for Cancer Research
Co-authored papers 1
Pasi A J??nne
Dana-Farber Cancer Institute
Co-authored papers 1
Oliver Hantschel
Institute of Physiological Chemistry, University of Marburg 35032 Marburg Germany .
Co-authored papers 1
Richard D Unwin
Co-authored papers 1
Shadmehr Demehri
Massachusetts General Hospital and Harvard Medical School
Co-authored papers 1
Anthony D Whetton
Co-authored papers 1
Raji Pillai
Jawaharlal Institute of Post-graduate Medical Education and Research
Co-authored papers 1
Anne M Dickinson
Translational and Clinical Research Institute, Newcastle University
Co-authored papers 1
Jorge Cortes
Georgia Cancer Center
Co-authored papers 1
Shannon K McWeeney
Oregon Health & Science University, University of California Berkeley
Co-authored papers 1
Marc M Loriaux
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 1
Stefan Kubicek
CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences
Co-authored papers 1
Neil E Caporaso
National Cancer Institute, National Institutes of Health
Co-authored papers 1
Zubin Master
Biomedical Ethics Research Program & Center for Regenerative Medicine, Mayo Clinic
Co-authored papers 1
Lucy C Pemberton
Southern District Health Board, Dunedin Hospital
Co-authored papers 1
Brian J P Huntly
University of Cambridge
Co-authored papers 1
Feyruz V Rassool
University of Maryland Greenebaum Comprehensive Cancer Center
Co-authored papers 1
Beth Wilmot
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 1
Release 1.2